BIOMAT Database Logo BIOMAT Database Logo

Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. 2013

Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
Janssen Research & Development, LLC, 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ 08560, USA. jkent@its.jnj.com

Efficacy and safety of 2 risperidone doses were evaluated in children and adolescents with autism. Patients (N = 96; 5-17 years), received risperidone (low-dose: 0.125 mg/day [20 to <45 kg], 0.175 mg/day [>45 kg] or high-dose: 1.25 mg/day [20 to <45 kg], 1.75 mg/day [>45 kg]) or placebo. Mean baseline (range 27-29) to endpoint change in Aberrant Behavior Checklist-Irritability (primary endpoint) was significantly greater in the high-dose-(-12.4 [6.5]; p < 0.001), but not low-dose (-7.4 [8.1]; p = 0.164) group, versus placebo (-3.5 [10.7]). Clinical Global Impressions-Severity and Children's Yale-Brown Obsessive Compulsive Scale scores improved significantly only in the high-dose group, consistent with ABC-I results. Somnolence, sedation and increased appetite occurred more frequently in high-versus low-dose groups. Overall, increased appetite occurred most frequently.

UI MeSH Term Description Entries
D008297 Male Males
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D001321 Autistic Disorder A disorder beginning in childhood. It is marked by the presence of markedly abnormal or impaired development in social interaction and communication and a markedly restricted repertoire of activity and interest. Manifestations of the disorder vary greatly depending on the developmental level and chronological age of the individual. (DSM-V) Autism, Infantile,Kanner's Syndrome,Autism,Autism, Early Infantile,Disorder, Autistic,Disorders, Autistic,Early Infantile Autism,Infantile Autism,Infantile Autism, Early,Kanner Syndrome,Kanners Syndrome

Related Publications

Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder.
October 2010, Progress in neuro-psychopharmacology & biological psychiatry,
Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
Memantine as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.
May 2013, The international journal of neuropsychopharmacology,
Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
Minocycline as Adjunctive Treatment to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial.
November 2016, Journal of child and adolescent psychopharmacology,
Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial.
January 2013, Psychopharmacology,
Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
July 1998, Archives of general psychiatry,
Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder.
September 2008, Child psychiatry and human development,
Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
Risperidone in children with autism: randomized, placebo-controlled, double-blind study.
June 2006, Journal of child neurology,
Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
Naltrexone in autistic children: a double-blind and placebo-controlled study.
January 1990, Psychopharmacology bulletin,
Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
February 2018, Journal of child and adolescent psychopharmacology,
Justine M Kent, and Stuart Kushner, and Xiaoping Ning, and Keith Karcher, and Seth Ness, and Michael Aman, and Jaskaran Singh, and David Hough
Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.
October 2005, The Journal of clinical psychiatry,
Copied contents to your clipboard!